Welcome to our dedicated page for Scilex Holding news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding stock.
Scilex Holding Company reports developments tied to its non-opioid pain management business, pharmaceutical assets and related healthcare investments. The company acquires, develops and commercializes products for acute and chronic pain, including ZTlido for postherpetic neuralgia, ELYXYB for acute migraine treatment in adults and Gloperba for prophylaxis of gout flares in adults.
Recurring Scilex news also includes material agreements, capital-structure actions, shareholder distributions involving Dream Bowl tokens, intellectual property and litigation counsel matters, strategic investments, clinical or regulatory disclosures, governance updates and operating and financial results.
Datavault AI (NASDAQ:DVLT) and Wellgistics Health (NASDAQ:WGRX) signed a fully binding term sheet to form DelivMeds AI (ticker reserved: NASDAQ:MEDS) via three concurrent transactions.
The structure includes a PharmacyChain™ HaaS license expansion, acquisition of QOLPOM biometric and drone logistics IP, and a controlling stake in Tollo Health, with an expected combined asset value of about $4 billion, subject to an independent fairness opinion and customary closing conditions.
Scilex Holding Company (Nasdaq: SCLX) announced that subsidiaries ACEA Therapeutics and ACEA Pharma entered a definitive agreement to sell 100% of ACEA Pharma to Phoenix Asia Holdings (Nasdaq: PHOE) for $1,000,000,000 via 100,000,000 newly issued Phoenix shares at $10.00 per share.
Upon closing, expected by end of Q2 2026 and subject to regulatory and Nasdaq approval, Phoenix will be renamed ACEA Pharma, Inc. and ACEA Thera is expected to own approximately 82% of the Go-Forward Company.
Scilex Holding Company (Nasdaq: SCLX) announced its Board set May 26, 2026 as the payment date for a previously announced dividend of Dream Bowl Meme Coin I tokens to holders of record as of April 30, 2026. Record Holders receive 5 Dream Bowl Tokens per share. Scilex holds ~268 million Dream Bowl Tokens and plans to distribute ~81.4 million. The company intends to list the tokens on Biconomy in Q2 2026. Receipt requires opening a Datavault digital wallet and executing an Opt-In Agreement. The tokens are described as digital collectibles and do not confer equity, voting, dividends, or monetary rights.
Datavault AI (NASDAQ: DVLT) executed a binding term sheet with Scilex for a $120 million cash contribution to fund a 100-city deployment of its quantum-ready SanQtum GPU edge network. The deal ties Scilex to a tiered revenue participation (30% → 15% → 5%) with caps of $250M and $1.2B. Datavault cites existing Nvidia GPUs valued at $1.2 billion and projects a combined $200M+ cash infusion without equity dilution; initial deployments in New York and Philadelphia target Q2 2026 with 100 locations within 36 months.
Scilex Holding Company (Nasdaq: SCLX) announced a dividend of Dream Bowl I meme coin tokens to holders of common stock and other eligible equity securities with a record date of April 30, 2026.
Participating holders will receive 5 Dream Bowl Tokens per share. Scilex holds ~268 million tokens and plans to distribute ~81.4 million. Payment will occur within 60 days after the record date, subject to Board discretion and an opt-in wallet process with Datavault.
Scilex Holding Company (Nasdaq: SCLX) announced a $20 million strategic investment in Quantum Scan Holdings, Inc. on January 30, 2026. The capital aims to support development and deployment of advanced diagnostic platforms, integrated analytics, and scalable healthcare solutions targeting large preventive diagnosis and prognosis markets.
Scilex said the investment complements its existing Datavault AI stake and seeks synergy with revenue-generating medical technology initiatives.
Scilex Holding Company (Nasdaq: SCLX) announced on Jan 2, 2026 the appointment of Kasowitz LLP and founding partner Marc Kasowitz as its litigation and intellectual property counsel. Kasowitz LLP will advise on complex commercial and patent litigation, IP enforcement and defense, licensing, and strategic IP governance as Scilex advances and protects its pharmaceutical assets and late-stage development pipeline.
A Scilex spokesperson said the appointment strengthens legal capabilities to support commercialization and shareholder value. Company product websites and contact information were provided.
Scilex Holding Company (Nasdaq: SCLX) confirmed a Dream Bowl 2026 Meme Coin claim process tied to a December 24, 2025 distribution. Eligible shareholders of record as of November 25, 2025 may claim allocated tokens any time after the December 24, 2025 distribution using the designated process at www.dreambowlcoin.com. The token program is powered by Datavault AI using encrypted blockchain infrastructure and real-world asset tokenization. The announcement positions the meme coin as a fusion of sports, digital assets, and shareholder perks. For corporate and product information, Scilex directs investors to its corporate and product websites.
Scilex Holding Company (Nasdaq: SCLX) closed the second tranche of its strategic investment in Datavault AI (Nasdaq: DVLT) on Nov 26, 2025, completing a two‑tranche equity financing.
Scilex purchased a pre‑funded warrant exercisable for 263,914,094 shares of Datavault common stock, paid in Bitcoin based on the spot rate at signing, and has exercised the warrant in full.
The shares issued upon exercise have an approximate value of $583.3 million based on Datavault's closing price of $2.21 on Nov 25, 2025. Datavault stockholder approval was obtained at the Nov 24, 2025 annual meeting. Both companies plan to ramp collaboration on Real World Asset tokenization in 2026.
Scilex Holding Company (Nasdaq: SCLX) announced the closing of reduced-price exercises of existing warrants, generating approximately $20.3 million gross proceeds on Nov 25, 2025. The exercises converted 904,396 shares of common stock at a reduced $22.51 per share.
In exchange, the company issued a new unregistered warrant to purchase up to 1,356,594 shares at a $29.00 exercise price, exercisable immediately for five years. Net proceeds are expected to be used for working capital and general corporate purposes.